Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy


Study Number
835120
Phase
I/II
Age Group
Adult
Purpose

An open-label, Phase 1/2 study of HPN328 as monotherapy to assess the safety, tolerability and PK in patients with advanced cancers associated with expression of DLL3.

Full Title

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 in Patients with Advanced Cancers Associated with Expression of Delta-Like Canonical Notch Ligand 3 (DLL3) Who Have…

ClinicalTrials.Gov ID
NCT04471727

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.